✦ LIBER ✦

Efficacy of memantine in PDD and DLB: an extension study including washout and open-label treatment

✍ Scribed by C. Johansson; C. Ballard; O. Hansson; S. Palmqvist; L. Minthon; D. Aarsland; E. Londos

Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 244 KB
Volume: 26
Category: Article
ISSN: 0885-6230
DOI: 10.1002/gps.2516

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and Efficacy of a Milk-derived Ex

Safety and Efficacy of a Milk-derived Extract in the Treatment of Plaque Psoriasis:An Open-label Study

✍ Y. Poulin; Y. Pouliot; E. Lamiot; N. Aattouri; S. F. Gauthier 📂 Article 📅 2005 🏛 Springer-Verlag 🌐 English ⚖ 155 KB

Results from an open-label extension stu

Results from an open-label extension study of etanercept in ankylosing spondylitis

✍ Davis, John ;Webb, Allison ;Lund, Steven ;Sack, Kenneth 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB 👁 2 views

COPD ϭ chronic obstructive pulmonary disease. 300 Letters \* RA ϭ rheumatoid arthritis; JRA ϭ juvenile rheumatoid arthritis; ESR ϭ erythrocyte sedimentation rate; CRP ϭ C-reactive protein; VAS ϭ visual analog scale; GH ϭ general health; DAS28 ϭ Disease Activity Score in 28 joints; HAQ ϭ Health Asses

The efficacy of reboxetine in the treatm

The efficacy of reboxetine in the treatment-refractory patients with panic disorder: an open label study

✍ P. N. Dannon; I. Iancu; L. Grunhaus 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB 👁 2 views

## Abstract ## Background and Objective Selective serotonin reuptake inhibitors (SSRIs) are currently the first‐line treatment for panic disorder, although up to 30% of patients either do not respond to SSRIs or withdraw due to adverse events. Reboxetine, a selective norepinephrine reuptake inhibi

Rituximab in the treatment of dermatomyo

Rituximab in the treatment of dermatomyositis: An open-label pilot study

✍ Todd D. Levine 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB 👁 2 views

Open label, multicenter, 28-week extensi

Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer’s disease

✍ Brian R. Ott; Lesley M. Blake; Ethel Kagan; Malca Resnick; for the Memantine MEM 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 142 KB

Safety and efficacy of olanzapine monoth

Safety and efficacy of olanzapine monotherapy in treatment-resistant bipolar mania: a 12-week open-label study

✍ Jun Chen; David J. Muzina; David E. Kemp; Carla Conroy; Philip Chan; Mary Beth S 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 190 KB

## Objective To examine the safety and efficacy of olanzapine monotherapy in treatment‐resistant bipolar mania. ## Method Subjects (__n__ = 18) who were acutely manic, did not respond to lithium, anticonvulsants, and neuroleptics, and/or had intolerable side effects to them in previous manic epis